June 8, 2016
(New Scientist) – A controversial “three-parent” gene fertility treatment has been tested successfully in healthy human embryos for the first time. The treatment aims to create embryos free of hereditary mitochondrial disease, and may now be considered safe enough to start human trials within one to two years. The potential beneficiaries would be children otherwise at risk of serious disease because their mothers pass down defective mitochondria, the “power packs” that provide energy to all living cells. Without healthy mitochondria, children can develop a range of degenerative disorders because their cells don’t work properly.
The views, opinions and positions expressed by these authors and blogs are theirs and do not necessarily represent that of the Bioethics Research Library and Kennedy Institute of Ethics or Georgetown University.